<DOC>
	<DOCNO>NCT00463385</DOCNO>
	<brief_summary>The purpose study determine safety select treatment regimen pomalidomide ( CC-4047 ) either single-agent combination prednisone study patient myelofibrosis myeloid metaplasia ( MMM ) .</brief_summary>
	<brief_title>A Phase II Study Pomalidomide Myelofibrosis With Myeloid Metaplasia</brief_title>
	<detailed_description>Participants receive study treatment Double Blind Treatment Phase 12 cycle ( 336 day ; 12 cycle 28 day ) . Participants complete Double-Blind Treatment Phase unblinded , receive pomalidomide determine complete remission ( CR ) , partial remission ( PR ) clinical improvement ( CI ) use International Working Group ( IWG ) Response Criteria study protocol , could continue current dose pomalidomide disease progression . Participants receive placebo discontinue study .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must sign inform consent form Must &gt; 18 year age Must diagnose myelofibrosis Eligibility base local pathology review bone marrow aspirate biopsy Screening total hemoglobin level &lt; 10g/dL transfusiondependent anemia define per International Working Group ( IWG ) criterion . Must adequate organ function demonstrate follow ≤ 14 day prior start study drug : Alanine aminotransferase ( ALT ; SGPT ) /aspartate aminotransferase ( AST ; SGOT ) ≤ 3 x upper limit normal ( ULN ) , [ unless upon judgment treat physician , believe due extramedullary hematopoiesis ( EMH ) ] . Total Bilirubin &lt; 3x ULN Direct Bilirubin &lt; 2 x ULN Serum creatinine ≤ 2.0 mg/dL Absolute neutrophil count ≥ 1,000/μL ( ≥ 1 x 10^9/L ) . Platelet count ≥ 50,000 /μL ( ≥ 50 x 10^9/L ) . Patients must willing receive transfusion blood product Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 screening . Must able adhere study visit schedule protocol requirement . No active malignancy exception control prostate cancer , basal cell squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . Must agree follow pregnancy precaution require per protocol Known positive status human immunodeficiency virus ( HIV ) , hepatitis B carrier , active hepatitis C infection . Previous untoward reaction corticosteroid ( specifically , prednisone ) therapy severe enough , opinion treat physician , preclude study participation . The use growth factor , cytotoxic chemotherapeutic agent ( e.g . hydroxyurea anagrelide ) , corticosteroid , experimental drug therapy within minimum 28 day start CC4047 and/or lack recovery toxicity previous therapy grade 1 better ( e.g . alpha interferon may require 84 day longer washout ) . Prior therapy CC4047 , lenalidomide thalidomide Myelofibrosis myeloid metaplasia ( MMM ) . ( Prior prednisone use therapy MMM allow , within 28 day start CC4047 ) . History deep vein thrombosis pulmonary embolism within one year start study medication . Any serious medical condition psychiatric illness would prevent , ( judge treat physician ) subject signing informed consent form condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Celgene</keyword>
	<keyword>CC-4047</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>myelofibrosis myeloid metaplasia</keyword>
	<keyword>myeloid metaplasia</keyword>
	<keyword>JAK2</keyword>
	<keyword>CC-4047-MMM-001</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Phase II</keyword>
	<keyword>pomalidomide</keyword>
	<keyword>bone marrow histology</keyword>
	<keyword>imids</keyword>
	<keyword>MMM</keyword>
	<keyword>Ashkenazi Jewish Population</keyword>
	<keyword>exposure Thorotrast</keyword>
	<keyword>exposure solvent ( benzene toluene )</keyword>
	<keyword>acute megakaryocytic leukemia</keyword>
	<keyword>history polycythemia vera</keyword>
</DOC>